Linda A DiMeglio1, Peiyao Cheng2, Roy W Beck2, Craig Kollman2, Katrina J Ruedy2, Robert Slover3, Tandy Aye4, Stuart A Weinzimer5, Andrew A Bremer6, Bruce Buckingham4. 1. Department of Pediatrics, Section of Pediatric Endocrinology/Diabetology, Indiana University, Riley Hospital for Children, Indianapolis, IN, USA. 2. Jaeb Center for Health Research, Tampa, FL, USA. 3. Barbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO, USA. 4. Pediatric Endocrinology, Stanford University, Stanford, CA, USA. 5. Pediatric Endocrinology, Yale University, New Haven, CT, USA. 6. Division of Pediatric Endocrinology, Vanderbilt University Medical Center, Nashville, TN, USA.
Abstract
OBJECTIVE: Prior studies examining beta-cell preservation in type 1 diabetes have predominantly assessed stimulated C-peptide concentrations approximately 10 wk after diagnosis. We examined whether earlier assessments might aid in prediction of beta cell function over time. METHODS: Using data from a multi-center randomized trial assessing the effect of intensive diabetes management initiated within 1 wk of diagnosis, we assessed which clinical factors predicted 90-min mixed-meal tolerance test (MMTT) stimulated C-peptide values obtained 2 and 6 wk after diagnosis. We also studied associations of these factors with C-peptide values at 1- and 2-year post-diagnosis. Data from intervention and control groups were pooled. RESULTS: Among 67 study participants (mean age 13.3 ± 5.7 yr, range 7.8-45.7 yr) in multivariable analyses, C-peptide increased from baseline to 2 wks and then 6 wk. C-peptide levels at these times were significantly correlated with 1- and 2-yr C-peptide concentrations (all p < 0.001), with the strongest observed associations between 6-wk C-peptide and the 1- and 2-yr values (r = 0.66 and r = 0.61, respectively). In multivariable analyses, greater baseline and 6-wk C-peptide, and older age independently predicted greater 1- and 2-yr C-peptide concentrations. CONCLUSIONS:C-peptide assessments close to diagnosis were predictive of subsequent C-peptide production. Our data demonstrate a clear increase in C-peptide over the initial 6 wk after diabetes diagnosis followed by a plateau. Our data do not suggest that MMTT assessments performed closer to diagnosis than 6 wk would improve prediction of subsequent residual beta cell function.
RCT Entities:
OBJECTIVE: Prior studies examining beta-cell preservation in type 1 diabetes have predominantly assessed stimulated C-peptide concentrations approximately 10 wk after diagnosis. We examined whether earlier assessments might aid in prediction of beta cell function over time. METHODS: Using data from a multi-center randomized trial assessing the effect of intensive diabetes management initiated within 1 wk of diagnosis, we assessed which clinical factors predicted 90-min mixed-meal tolerance test (MMTT) stimulated C-peptide values obtained 2 and 6 wk after diagnosis. We also studied associations of these factors with C-peptide values at 1- and 2-year post-diagnosis. Data from intervention and control groups were pooled. RESULTS: Among 67 study participants (mean age 13.3 ± 5.7 yr, range 7.8-45.7 yr) in multivariable analyses, C-peptide increased from baseline to 2 wks and then 6 wk. C-peptide levels at these times were significantly correlated with 1- and 2-yr C-peptide concentrations (all p < 0.001), with the strongest observed associations between 6-wk C-peptide and the 1- and 2-yr values (r = 0.66 and r = 0.61, respectively). In multivariable analyses, greater baseline and 6-wk C-peptide, and older age independently predicted greater 1- and 2-yr C-peptide concentrations. CONCLUSIONS:C-peptide assessments close to diagnosis were predictive of subsequent C-peptide production. Our data demonstrate a clear increase in C-peptide over the initial 6 wk after diabetes diagnosis followed by a plateau. Our data do not suggest that MMTT assessments performed closer to diagnosis than 6 wk would improve prediction of subsequent residual beta cell function.
Authors: Stephen E Gitelman; Peter A Gottlieb; Mark R Rigby; Eric I Felner; Steven M Willi; Lynda K Fisher; Antoinette Moran; Michael Gottschalk; Wayne V Moore; Ashley Pinckney; Lynette Keyes-Elstein; Sudeepta Aggarwal; Deborah Phippard; Peter H Sayre; Linna Ding; Jeffrey A Bluestone; Mario R Ehlers Journal: Lancet Diabetes Endocrinol Date: 2013-08-28 Impact factor: 32.069
Authors: Mark R Rigby; Linda A DiMeglio; Marc S Rendell; Eric I Felner; Jean M Dostou; Stephen E Gitelman; Chetanbabu M Patel; Kurt J Griffin; Eva Tsalikian; Peter A Gottlieb; Carla J Greenbaum; Nicole A Sherry; Wayne V Moore; Roshanak Monzavi; Steven M Willi; Philip Raskin; Antoinette Moran; William E Russell; Ashley Pinckney; Lynette Keyes-Elstein; Michael Howell; Sudeepta Aggarwal; Noha Lim; Deborah Phippard; Gerald T Nepom; James McNamara; Mario R Ehlers Journal: Lancet Diabetes Endocrinol Date: 2013-09-23 Impact factor: 32.069
Authors: Jerry P Palmer; G Alexander Fleming; Carla J Greenbaum; Kevan C Herold; Lisa D Jansa; Hubert Kolb; John M Lachin; Kenneth S Polonsky; Paolo Pozzilli; Jay S Skyler; Michael W Steffes Journal: Diabetes Date: 2004-01 Impact factor: 9.461
Authors: Carla J Greenbaum; Thomas Mandrup-Poulsen; Paula Friedenberg McGee; Tadej Battelino; Burkhard Haastert; Johnny Ludvigsson; Paolo Pozzilli; John M Lachin; Hubert Kolb Journal: Diabetes Care Date: 2008-07-15 Impact factor: 19.112
Authors: Rachel E J Besser; Beverley M Shields; Rosaura Casas; Andrew T Hattersley; Johnny Ludvigsson Journal: Diabetes Care Date: 2012-10-30 Impact factor: 19.112
Authors: Bruce Buckingham; Roy W Beck; Katrina J Ruedy; Peiyao Cheng; Craig Kollman; Stuart A Weinzimer; Linda A DiMeglio; Andrew A Bremer; Robert Slover; William V Tamborlane Journal: Diabetes Care Date: 2013-10-15 Impact factor: 19.112
Authors: Andrea K Steck; Helena Elding Larsson; Xiang Liu; Riitta Veijola; Jorma Toppari; William A Hagopian; Michael J Haller; Simi Ahmed; Beena Akolkar; Åke Lernmark; Marian J Rewers; Jeffrey P Krischer Journal: Pediatr Diabetes Date: 2017-01-27 Impact factor: 3.409